Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.75Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: 1.18%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted the successful launch and adoption of EluPro, significant improvement in gross margins, and progress in reducing litigation liabilities. However, the company faced challenges with a decline in overall revenue, Simpliderm sales, and cardiovascular sales. Despite these challenges, the strong performance and growth prospects of EluPro contribute to a positive outlook.Company Guidance
During the Elutia Inc. conference call for the fourth quarter and full year 2024 financial results, the company provided guidance with several key metrics. Elutia's flagship product, EluPro, has been FDA cleared for use in cardiac implantable electronic devices and neurostimulators, entering a market with approximately 600,000 pacemakers and internal defibrillators placed annually in the U.S. The company reported $2.7 million in device protection sales for the quarter, an 18% increase compared to the same quarter last year, contributing to a total of $9.9 million for the year, representing a 5% annual growth. The gross margin excluding non-cash amortization expense rose to 58% in the fourth quarter from 51% the previous year. Operational excellence was demonstrated with a gross margin target north of 70%, and Elutia achieved a significant milestone with 67 value analysis committee approvals, surpassing their goal of 25 for the quarter. Looking ahead, Elutia plans to expand production capacity and leverage their partnership with Boston Scientific to further increase market penetration and sales growth.Successful EluPro Launch
Elutia Inc. launched EluPro, receiving FDA clearance for use in cardiac implantable electronic devices and neurostimulators. The pilot launch exceeded expectations, demonstrating operational excellence, obtaining hospital and GPO approval, and driving clinical uptake.
Strong Pilot Launch Performance
EluPro accounted for 30% of bio envelope sales during the fourth quarter, with bio envelope sales up 18% for the quarter. EluPro has been adopted in about 100 centers and is actively being ordered, with significant support from physicians.
Gross Margin Improvement
The GAAP gross margin increased to 43% for the quarter from 36% in the prior year. Excluding non-cash amortization, the gross margin was 58% versus 51% in the previous year.
Reduction of Litigation Liabilities
Elutia Inc. reduced its litigation liability related to the fiber cell litigation from over $20 million to $15.9 million, with the number of outstanding cases decreasing from 79 to 43.
---
ELUT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ELUT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $2.55 | $2.78 | +9.02% |
| Nov 14, 2024 | $3.83 | $3.56 | -7.05% |
| Aug 07, 2024 | $2.84 | $3.07 | +8.10% |
| May 09, 2024 | $2.80 | $3.29 | +17.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aziyo Biologics (ELUT) report earnings?
Aziyo Biologics (ELUT) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Aziyo Biologics (ELUT) earnings time?
Aziyo Biologics (ELUT) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELUT EPS forecast?
ELUT EPS forecast for the fiscal quarter 2025 (Q1) is -0.21.
---